Take Solutions Ltd
Incorporated in 2000, TAKE Solutions Ltd is in the business of Life Sciences and Support Services[1]
- Market Cap ₹ 369 Cr.
- Current Price ₹ 24.9
- High / Low ₹ 25.0 / 6.51
- Stock P/E 44.2
- Book Value ₹ 1.74
- Dividend Yield 0.00 %
- ROCE 18.0 %
- ROE 16.7 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
Cons
- Stock is trading at 14.3 times its book value
- The company has delivered a poor sales growth of -18.3% over past five years.
- Company has a low return on equity of -22.8% over last 3 years.
- Working capital days have increased from 1,495 days to 5,406 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 26 | 24 | 19 | 2 | 22 | 2 | 11 | 18 | 56 | 5 | 1 | 0 | |
| 22 | 24 | 18 | 22 | 19 | 36 | 19 | 18 | 31 | 53 | 15 | 3 | 4 | |
| Operating Profit | 4 | 1 | 5 | -4 | -16 | -14 | -17 | -7 | -13 | 3 | -10 | -2 | -4 |
| OPM % | 14% | 6% | 22% | -19% | -664% | -63% | -685% | -64% | -74% | 5% | -176% | -228% | |
| 22 | 13 | 16 | 22 | 33 | 34 | 26 | 15 | -460 | 4 | -192 | -67 | -19 | |
| Interest | 2 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Depreciation | 5 | 1 | 0 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 0 | 0 |
| Profit before tax | 18 | 13 | 20 | 15 | 15 | 20 | 7 | 7 | -475 | 5 | -203 | -70 | -24 |
| Tax % | 5% | 15% | 10% | 1% | -3% | 11% | -11% | -20% | 0% | 9% | 2% | 0% | |
| 17 | 11 | 18 | 14 | 15 | 17 | 8 | 8 | -477 | 4 | -207 | -70 | -24 | |
| EPS in Rs | 1.40 | 0.92 | 1.49 | 1.08 | 1.03 | 1.18 | 0.52 | 0.53 | -32.26 | 0.29 | -14.01 | -4.71 | -1.63 |
| Dividend Payout % | 70% | 106% | 66% | 92% | 155% | 85% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -29% |
| 5 Years: | -18% |
| 3 Years: | -63% |
| TTM: | -100% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 6% |
| 3 Years: | 26% |
| TTM: | 130% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -18% |
| 5 Years: | -10% |
| 3 Years: | 1% |
| 1 Year: | 42% |
| Return on Equity | |
|---|---|
| 10 Years: | -11% |
| 5 Years: | -32% |
| 3 Years: | -23% |
| Last Year: | 17% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 13 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
| Reserves | 308 | 304 | 307 | 505 | 755 | 748 | 751 | 760 | 284 | 288 | 81 | 11 |
| 0 | 0 | 73 | 0 | 0 | 0 | 4 | 0 | 2 | 2 | 0 | 0 | |
| 11 | 9 | 22 | 16 | 7 | 12 | 7 | 11 | 11 | 14 | 24 | 6 | |
| Total Liabilities | 331 | 325 | 414 | 534 | 777 | 774 | 776 | 786 | 312 | 319 | 119 | 32 |
| 2 | 1 | 0 | 5 | 4 | 3 | 6 | 4 | 3 | 2 | 0 | 0 | |
| CWIP | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 284 | 234 | 330 | 360 | 414 | 512 | 517 | 517 | 155 | 243 | 102 | 0 |
| 45 | 90 | 81 | 170 | 359 | 259 | 253 | 265 | 154 | 74 | 17 | 32 | |
| Total Assets | 331 | 325 | 414 | 534 | 777 | 774 | 776 | 786 | 312 | 319 | 119 | 32 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37 | -3 | -11 | -33 | -24 | 13 | -15 | -3 | 33 | 27 | -4 | -20 | |
| -19 | 55 | -92 | -24 | -88 | -112 | 22 | 13 | -40 | -22 | -1 | 22 | |
| -23 | -12 | 61 | 58 | 239 | -28 | -8 | -0 | -1 | -1 | -0 | -0 | |
| Net Cash Flow | -5 | 41 | -42 | 1 | 127 | -127 | -1 | 11 | -9 | 4 | -6 | 3 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 36 | 43 | 58 | 62 | 136 | 107 | 1,034 | 81 | 87 | 0 | 0 | 0 |
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 36 | 43 | 58 | 62 | 136 | 107 | 1,034 | 81 | 87 | 0 | 0 | 0 |
| Working Capital Days | 303 | 394 | -732 | 1,958 | 26,943 | 3,456 | 33,992 | 7,839 | 1,844 | 242 | -1,163 | 5,406 |
| ROCE % | 6% | 4% | 4% | 4% | 2% | 2% | 1% | -1% | 0% | 4% | -5% | 18% |
Documents
Announcements
-
Board Meeting Intimation for Notice Of Board Meeting
22 Oct - TAKE Solutions board meeting Oct 27, 2025 to approve Q2/H1 unaudited results ended Sep 30, 2025.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Oct - RTA confirms compliance with SEBI Regulation 74(5) for quarter ended 30 September 2025.
-
Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors
9 Oct - Sundar Srini & Sridhar resigning as statutory auditors after Q2 review; fee disagreement cited (letter dated 08-Oct-2025).
-
Disclosure Under Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015
6 Oct - Promoter-group Esyspro sold 14,497,532 shares off-market on 30-Sep-2025; stake fell to 5.10%
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 4 Oct
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Dec 2020TranscriptPPT
-
Sep 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Mar 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Aug 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Feb 2018TranscriptPPT
-
Nov 2017TranscriptPPT
-
Nov 2017TranscriptPPT
-
Aug 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Jan 2017TranscriptPPT
-
Dec 2016TranscriptPPT
-
Oct 2016TranscriptPPT
-
Feb 2016TranscriptNotesPPT
Business Overview:[1]
Singapore-based TAKE Solutions Pte Limited holds a 52.90% stake in TSL, serving as the holding company. TSL specializes in Life Sciences and Supply Chain Management, providing comprehensive services in clinical development and specific offerings in supply chain. The company is involved in clinical trials, generics support, including bio-availability & bioequivalent studies, regulatory filing, and pharmacovigilance.